A Phase I Clinical Study of Oral ZL-65 Tablets in Healthy and Obese Participants With Cardiovascular Risk
A Randomized, Double-blind, Placebo-controlled, Single and Multiple-dose Administration, Dose-escalation Phase I Clinical Study Evaluating the Safety, Tolerability, Pharmacokinetic, Pharmacodynamics Characteristics and the Effect of Food on Pharmacokinetics of Oral ZL-65 Tablets in Healthy and Obese Participants With Cardiovascular Risk
This study comprised of 3 parts, gradually investigating the safety, tolerance, PK and PD characteristics of the ZL-65 tablets in healthy adult participants and obesity with cardiovascular risk participants in Australia. The study results will provide important basis for formulating the subsequent study strategies and dosing plans.Part 1: Single-ascending Dose (SAD) study and Food Effect (FE) study;Part 2: Multiple-ascending Doses (MAD) study;Part 3: Obesity with cardiovascular risk study.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Phase 1
Contacts and Locations
Study Contact
Study Contact
- Name: Sun Haibin
- Phone Number: +8618200237928
- Email: sunhaibin@zenitar.cn
Study Locations
-
-
-
Melbourne, Australia
- Nucleus Network Pty Ltd Commercial Road
-
Contact:
- Ofer Gonen, Doctor
- Phone Number: 03 8593 9801
- Email: o.gonen@nucleusnetwork.com.au
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- All participants must:1, Healthy adult participants, regardless of gender, aged between 18 and 65 years old when the informed consent is signed; 2,Male participants with a body weight of >= 50.0 kg, female participants with a body weight of >= 45.0 kg; 3, Those who can understand the informed consent form, voluntarily participate in the trial and sign the informed consent form.
Exclusion Criteria:
- Individuals with allergic constitution, or those with a history of clinically significant food, drug allergies or other allergic reactions as determined by the investigators; or those who are known to be allergic to NLRP3 inhibitors or to the excipient ingredients of the IP;
- Diabetes mellitus;
- Hypertension;
- Hepatobiliary diseases;
- Alcoholism;
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Single-ascending Dose (SAD) study and Food Effect (FE) study
|
The SAD portion of the study consists of 5 cohorts. Dosing in these cohorts will precede sequentially: 5 mg, 10 mg, 25 mg, 40 mg and 50 mg cohorts. |
|
Experimental: Multiple-ascending Doses (MAD) study
|
The MAD portion of the study consists of 3 cohorts. Dosing in these cohorts will precede sequentially:10 mg, 25 mg and 40 mg cohorts. |
|
Experimental: Obesity with cardiovascular risk study
|
This study intends to set up 2 dose cohorts, temporarily as follows: 1) 10 mg QD cohort, 2) 25 mg QD cohort. |
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Incidence of adverse events
Time Frame: Day 1 to Day 21
|
including hematology, blood biochemistry, urinalysis, and coagulation function |
Day 1 to Day 21
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
ZL65 Pharmacokinetics (PK):Cmax
Time Frame: 0-144 hours
|
0-144 hours
|
|
ZL65 Pharmacokinetics (PK):Tmax
Time Frame: 0-144 hours
|
0-144 hours
|
|
ZL65 Pharmacokinetics (PK):AUC0-t
Time Frame: 0-144 hours
|
0-144 hours
|
|
ZL65 Pharmacokinetics (PK):t1/2
Time Frame: 0-144 hours
|
0-144 hours
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Ofer Gonen, Doctor, Nucleus Network Pty Ltd Commercial Road
Study record dates
Study Major Dates
Study Start (Estimated)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Investigative Techniques
- Diagnostic Techniques and Procedures
- Diagnosis
- Physiological Phenomena
- Biochemical Phenomena
- Chemical Phenomena
- Physical Examination
- Body Size
- Body Weights and Measures
- Body Constitution
- Anthropometry
- Metabolism
- Body Fat Distribution
- Body Composition
- mycophenolic adenine dinucleotide
- Sagittal Abdominal Diameter
- Adiposity
Other Study ID Numbers
Other Study ID Numbers
- O-ZL65-PI-I
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.